These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

221 related articles for article (PubMed ID: 20881214)

  • 1. Model-based drug development survey finds pharmacometrics impacting decision making in the pharmaceutical industry.
    Stone JA; Banfield C; Pfister M; Tannenbaum S; Allerheiligen S; Wetherington JD; Krishna R; Grasela DM
    J Clin Pharmacol; 2010 Sep; 50(9 Suppl):20S-30S. PubMed ID: 20881214
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Model-based drug development: strengths, weaknesses, opportunities, and threats for broad application of pharmacometrics in drug development.
    Wetherington JD; Pfister M; Banfield C; Stone JA; Krishna R; Allerheiligen S; Grasela DM
    J Clin Pharmacol; 2010 Sep; 50(9 Suppl):31S-46S. PubMed ID: 20881215
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Fostering culture and optimizing organizational structure for implementing model-based drug development.
    Zhang L; Allerheiligen SR; Lalonde RL; Stanski DR; Pfister M
    J Clin Pharmacol; 2010 Sep; 50(9 Suppl):146S-150S. PubMed ID: 20881228
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacometrics 2020.
    Gobburu JV
    J Clin Pharmacol; 2010 Sep; 50(9 Suppl):151S-157S. PubMed ID: 20881229
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Interactive visualization and communication for increased impact of pharmacometrics.
    Krause A; Gieschke R
    J Clin Pharmacol; 2010 Sep; 50(9 Suppl):140S-145S. PubMed ID: 20881227
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Concepts and challenges in quantitative pharmacology and model-based drug development.
    Zhang L; Pfister M; Meibohm B
    AAPS J; 2008 Dec; 10(4):552-9. PubMed ID: 19003542
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A decade of fragment-based drug design: strategic advances and lessons learned.
    Hajduk PJ; Greer J
    Nat Rev Drug Discov; 2007 Mar; 6(3):211-9. PubMed ID: 17290284
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacometrics as a discipline is entering the "industrialization" phase: standards, automation, knowledge sharing, and training are critical for future success.
    Romero K; Corrigan B; Tornoe CW; Gobburu JV; Danhof M; Gillespie WR; Gastonguay MR; Meibohm B; Derendorf H
    J Clin Pharmacol; 2010 Sep; 50(9 Suppl):9S-19S. PubMed ID: 20881213
    [No Abstract]   [Full Text] [Related]  

  • 9. Impact of pharmacometrics on drug approval and labeling decisions: a survey of 42 new drug applications.
    Bhattaram VA; Booth BP; Ramchandani RP; Beasley BN; Wang Y; Tandon V; Duan JZ; Baweja RK; Marroum PJ; Uppoor RS; Rahman NA; Sahajwalla CG; Powell JR; Mehta MU; Gobburu JV
    AAPS J; 2005 Oct; 7(3):E503-12. PubMed ID: 16353928
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Development of antituberculous drugs: current status and future prospects].
    Tomioka H; Namba K
    Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Probabilistic risk analysis: improving early drug development decision making.
    Mudd PN; Groenendaal H; Bush MA; Schmith VD
    Clin Pharmacol Ther; 2010 Dec; 88(6):871-5. PubMed ID: 20944562
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Induction of drug metabolizing enzymes: a survey of in vitro methodologies and interpretations used in the pharmaceutical industry--do they comply with FDA recommendations?
    Hewitt NJ; de Kanter R; LeCluyse E
    Chem Biol Interact; 2007 May; 168(1):51-65. PubMed ID: 17239835
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Should pharmacometrics be training the next R&D president?
    Gobburu JV
    Clin Pharmacol Ther; 2014 Jun; 95(6):579-80. PubMed ID: 24842637
    [TBL] [Abstract][Full Text] [Related]  

  • 14. New Zealand's drug development industry--strengths and opportunities.
    Lockhart MM; Babar ZU; Garg S
    N Z Med J; 2010 Jun; 123(1317):52-8. PubMed ID: 20657631
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Alternative strategies in drug development: clinical pharmacological aspects.
    Kuhlmann J
    Int J Clin Pharmacol Ther; 1999 Dec; 37(12):575-83. PubMed ID: 10599949
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Compound scale-up at the discovery-development interface.
    Nikitenko AA
    Curr Opin Drug Discov Devel; 2006 Nov; 9(6):729-40. PubMed ID: 17117683
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Early communication of drug safety concerns: a feasibility study on enhancing interaction between the pharmaceutical industry and regulators.
    Swain E; Morgan S; Brewster W; Kauser S
    Pharmacoepidemiol Drug Saf; 2010 Mar; 19(3):232-7. PubMed ID: 20033909
    [TBL] [Abstract][Full Text] [Related]  

  • 18. An industry survey on current practices in the design and analysis of active control studies.
    Chuang-Stein C; Sanders C; Snapinn S
    J Biopharm Stat; 2004 May; 14(2):349-58. PubMed ID: 15206532
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Impact of hepatic uptake transporters on pharmacokinetics and drug-drug interactions: use of assays and models for decision making in the pharmaceutical industry.
    Soars MG; Webborn PJ; Riley RJ
    Mol Pharm; 2009; 6(6):1662-77. PubMed ID: 19402709
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Model-based evaluation of QTc interval risk: an increasing emphasis on early decision making.
    Krishna R
    J Clin Pharmacol; 2009 Sep; 49(9):1010-1. PubMed ID: 19717724
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 12.